Chris Zhang

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

S. Tuchman, N. Callander, G. Schiller, 2021, British Journal of Cancer.

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

S. Tuchman, N. Callander, M. Leiba, 2021, Blood.

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

S. Tuchman, N. Callander, G. Schiller, 2022, Blood.

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

S. Tuchman, N. Callander, G. Schiller, 2021, EJHaem.

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

S. Tuchman, G. Schiller, R. Kotb, 2023, Clinical lymphoma, myeloma & leukemia.